Skip to main content
. 2020 Feb 13;46(2):285–297. doi: 10.1007/s00134-020-05949-z

Table 2.

RDTs for the detection of Ebola virus.

Adapted from Tembo et al. [35]

RDT type Manufacturer Target Turnaround time (min) Storage temperature (°C) Clinical validation status Sample
Ebola eZYSCREEN BioMérieux and Institut des sciences du vivant Frédéric Joliot, France EBOV GP 15 4–30 Yes Whole blood or plasma
ReEBOV antigen rapid test Zalgen Labs (previously Corgenix Ltd), USA EBOV, BDBV, and SUDV VP40 protein antigen 15 2–8 Yes Whole blood or plasma
ELISA antigen capture National Institute of Infectious Diseases, Japan RESTV NP protein antigen Hours 2–8 NR Serum
Ebola-specific IgM and Ig G antibody detection Corgenix USA EBOV and SUDV- specific antibodies against VP40 antigen Hours 2–8 Yes Serum
OraQuick® OraSure Technologies Inc, USA Detects Ebola VP40 antigen (EBOV, SUDV and BDBV) 20–30 4–30 Yes Whole blood and saliva (post mortem samples)
DSTL EVD RDT UK’s Defence Science Technology and Laboratory EBOV antigens (unspecified) 20 NR Yes Whole blood
Matrix Multiplexed diagnostic MMDX EBOV GP 10 NR NR Plasma and serum
SD Q Line Zaire Ag assay SD Biosensor Inc, Republic of Korea EBOV protein antigens (GP, NP and VP40) 30 1–40 Yes Whole blood, plasma and serum
QuickNavi-Ebola Denka Seiken, Japan EBOV, TAFV, BDBV, SUDV NP protein antigen 10 4–45 Yes Whole blood, plasma and serum
iSENSE University College London EBOV, SUDV, and BDBV Ig G 40 NR NR Venous blood

Clinical validation refers to field testing for specificity and sensitivity on blood specimens containing varying amounts of Ebola virus, with the specific RDT results compared to the polymerase chain reaction gold standard test [3740]

BDBV, Bundibugyo ebolavirus; GP, glycoprotein; Ig G, immunoglobulin G; Ig M, immunoglobulin M; VP, matrix protein; NP, nucleoprotein; NR, not reported; RESTV, Reston ebolavirus; SUDV, Sudan ebolavirus; TAFV, Taï Forest ebolavirus; EBOV, Zaire ebolavirus